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We investigated the impact of IRe1/eRN1 (inositol requiring enzyme 1/endoplasmic reticulum to nu-
cleus signaling 1) knockdown on hypoxic regulation of the expression of a subset of proliferation and migra-
tion-related genes in U87 glioma cells. It was shown that hypoxia leads to up-regulation of the expression of 
MeST and SNaI2, to down-regulation – of MyBl1, TcF8 and GTF2F2 genes at the mRNa level in control 
glioma cells. At the same time hypoxia does not affect the expression of TCF3 and GTF2B transcription factor 
genes. In turn, inhibition of IRE1 modifies the effect of hypoxia on the expression of all studied genes, except 
MyBl1 and GTF2B. For instance, IRe1 knockdown decreases sensitivity to hypoxia of the expression of 
MeST, TcF8 and SNaI2 genes and increases sensitivity to hypoxia of GTF2F2 expression. at the same time 
IRe1 inhibition introduces sensitivity to hypoxia of the expression of TcF3 gene in glioma cells. The present 
study demonstrates the inhibition of IRE1 in glioma cells affects the hypoxic regulation of the expression of 
genes studied. Hypoxic conditions do not abolish the effect of IRE1 inhibition on the expression of respective 
genes. To the contrary, in case of SNAI2, GTF2F2 and MEST hypoxic conditions magnify the effect of IRE1 
inhibition on the expression of respective genes in glioma cells. 
k e y  w o r d s: mRNa expression, MyBl1, TcF3, TcF8, SNaI2, GTF2B, GTF2F2, MeST, IRe1 inhibition, 
hypoxia, glioma cells.
T ranscription factors MYBL1 (Myb-like pro-tein 1), TCF3 (transcription factor 3), TCF8 (transcription factor 8), SNAI2 (Snail ho-
molog 2), GTF2B (general transcription factor IIB), 
GTF2F2 (general transcription factor IIF, polypep-
tide 2), as well as potential tumor suppressor MEST 
(mesoderm specific transcript) are implicated in 
control of various cellular processes, in particular, 
proliferation and migration [1-10]. Role of MYBL1 
transcription factor in tumor development is still un-
der investigation. However, it is known, that partial 
duplication of MyBl1 gene together with truncation 
of its C-terminal regulatory domain is frequently ob-
served in pediatric gliomas [7]. Transcription factor 
TCF3 functions both as transcriptional activator and 
repressor depending on its interactions with part-
ner proteins. For instance, CBP/p300 participates in 
transcriptional activation, whereas ETO family fac-
tors contribute to repression of transcription [1, 2]. 
Role of TCF3 in development of malignancies is 
ambiguous, but decreased expression of this factor 
correlates with negative prognosis in patients with 
colon cancer [3]. On the other hand, over-expression 
of TCF3 is observed in breast, stomach, kidney tu-
mors and hepatocellular carcinoma [4]. 
Among others, transcription factors SNAI2, 
TCF8 and TCF3 are identified as key regulators of 
invasive phenotype development in different types 
of tumors. These factors are pleiotropically ex-
pressed and there effects are partially redundant. 
For instance, SNAI2, TCF8 and TCF3 are negative 
regulators of E-cadherin expression, as they recog-
nize regulatory E-box elements in promoter region 
of this gene [4-6]. Experimental over-expression 
of transcription factors SNAIL, SNAI2, ZEB1/2 
of TWIST1/2 in epithelial cells leads, as a rule, to 
initiation of epithelial-mesenchymal transition: loss 
of adherent junctions, conversion of cells from po-
lygonal into fusiform, expression of enzymes, which 
cleave the components of extracellular matrix, in-
creased mobility and resistance to apoptosis [11, 12]. 
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PeG1/MeST (paternally expressed gene 1/ 
mesoderm specific transcript) is a gene, localized in 
chromosome 7q32.2, characterized by genome im-
printing, meaning that only its paternal allele is ex-
pressed, whereas the expression of maternal allele is 
blocked due to hypermethylation. This gene encodes 
an enzyme, which belongs to the family of alpha/
beta hydrolases [13]. It was demonstrated, that loss 
of methylation of one of the PeG1/MeST alleles in-
creases the risk of cervical cancer develop ment [14]. 
Aberrant PeG1/MeST imprinting was detected in in-
vasive breast tumors and uterine leiomyomas [15-17]. 
In case of hepatocellular carcinoma, in contrast, the 
down-regulation of PeG1/MeST expression is ob-
served due to hypermethylation of its promoter [8]. 
It is interesting to note, that one of the intrones of the 
PeG1/MeST gene codes a tumor suppressor micro-
RNA miR-335, which inhibits the metastatic abilities 
of tumor cells [8]. Therefore, the hypermethylation 
of the promoter of this gene consecutively decreases 
the expression of MEST and miR-335 [8]. It needs 
to be clarified to which extend the tumor suppressor 
effect of MeST is determined by the expression of its 
protein product or аn intron-localized miR-335. 
General transcription factor 2B is involved in 
RNA polymerase II recruitment and initiation of 
transcription in eukaryotes [18]. Recently, it was 
shown, that the expression of this transcription fac-
tor is increased in hepatocellular carcinoma in com-
parison to normal tissues on both mRNA and protein 
levels. Moreover, it was found that elevated levels 
of GTF2B in hepatocellular carcinoma cells are as-
sociated with transition from G1 to S phase, and cell 
growth assay shows that overexpression of TFIIB 
may promote cell proliferation [9]. 
GTF2F2 is an ATP-dependent DNA-helicase, 
which exists as a heterodimer with another general 
transcription factor GTF2F1. The complex is active 
in both initiation and elongation stages of transcrip-
tion controlling the activity of RNA polymerase II 
[19]. The possible significance of GTF2F2 for cancer 
development is still to be investigated, however, it is 
known, that this transcription factor is downregu-
lated in cervical cancer specimens in comparison 
to normal tissues [20, 21]. Recently, GTF2F2 was 
identified as a new target gene of a tumor suppres-
sor transcription factor delta-lactoferrin in MDA-
MB-231 breast cancer cells [10].
Presence of hypoxic regions in tumors increa-
ses their resistance to chemo- and radiotherapy, in 
particular, due to ineffective diffusion of drugs and 
slower cell division, which usually accompanies hy-
poxia. Moreover, cycles of hypoxia-reoxygenation 
increase the migration potential of tumor [22, 23]. 
For many types of tumor there is a correlation be-
tween HIF (hypoxia inducible factor) activation and 
decreased expression of E-cadherin, a key tumor 
suppressor, which inhibits epithelial-mesenchymal 
transition. In general, hypoxia modifies the physiolo-
gy of a neoplasm towards more aggressive pheno-
type [24]. 
Activation of an endoplasmic reticulum stress 
signaling pathway plays an important role in adapta-
tion of tumor cells to the decreased levels of oxygen. 
In particular, a protein kinase PERK is activated 
under hypoxic conditions, which leads to the phos-
phorylation of translation initiation factor eIF2α, and 
therefore – to overall decrease in protein synthesis. 
Moreover, PERK-mediated phosphorylation of eIF2α 
activates the translation of an ATF4 transcription 
factor, which facilitates cell survival under stressful 
conditions [25]. It is also known, that activation of 
PERK-dependent branch of endoplasmic reticulum 
stress facilitates the adaptation of cells to prolonged 
hypoxia and development of resistance to apopto-
sis [26]. Activation of IRE1 (inositol requiring en-
zyme-1)-dependent branch of endoplasmic reticulum 
stress pathway is no less important for the adaptation 
to hypoxic conditions. For instance, IRE1 activation 
leads to the expression of an active XBP1 (X-box 
protein 1) transcription factor, which promotes sur-
vival of tumor cells [27]. It was demonstrated, that 
VEGF expression and angiogenesis in tumors under 
hypoxic conditions is also IRE1-dependent [28]. 
Gliomas, as many other types of solid tumors, 
are characterized by the presence of hypoxic and ne-
crotic regions. Through activation of various signa-
ling pathways, in particular – endoplasmic reticulum 
stress response, gliomas utilize hypoxic conditions 
to stimulate the neovascularization, tumor growth 
and invasion [29].
In this study we investigated the impact of hy-
poxia on the expression of a subset of proliferation 
and migration-related genes in U87 glioma cells in 
relation to functional activity of a key endoplasmic 
reticulum stress effector IRE1. 
materials and methods
cell lines and culture conditions. The glioma 
cell line U87 (HTB-14) was obtained from ATCC 
(USA) and grown in high glucose (4.5 g/l) Dulbec-
co’s modified Eagle’s minimum essential medium 
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(DMEM; Gibco, Invitrogen, USA) supplemented 
with glutamine (2 mM), 10% fetal bovine serum 
(Equitech-Bio, Inc., USA), penicillin (100 units/ml; 
Gibco, USA) and streptomycin (0.1 mg/ml; Gibco) at 
37 °C in a 5% CO2 incubator. 
In this study we used sublines of U87 glioma 
cells, which were described previously [30-32]. One 
subline was obtained by selection of stable transfec-
ted clones with overexpression of vector pcDNA3.1, 
which was used for creation of dnERN1. Second sub-
line was obtained by selection of stable transfected 
clone with overexpression of IRE1 dominant-nega-
tive construct (dnERN1) and has suppressed protein 
kinase and endoribonuclease activities of this signal-
ing enzyme (clone 1C5) [31]. The expression level of 
studied genes in these two sublines of glioma cells 
was compared with corresponding cells, transfected 
by vector or by dnERN1 construct. The efficiency 
of IRE1 suppression in this glioma cell subline was 
estimated previously [33, 34]. Both used in this study 
sublines of glioma cells were grown with the addi-
tion of geneticin (G418) while these cells carrying 
empty vector pcDNA3.1 or dnERN1 construct.
For hypoxia culture plates were exposure in 
special chamber with 3% oxygen, 92% nitrogen, and 
5% carbon dioxide levels for 16 h.
RNa isolation. Total RNA was extracted from 
glioma cells using Trizol reagent according to man-
ufacturer protocols (Invitrogen, USA) as described 
previously [34]. The RNA pellets were washed with 
75% ethanol and dissolved in nuclease-free wa-
ter. For additional purification, RNA samples were 
re-precipitated with 95% ethanol and re-dissolved 
again in nuclease-free water. RNA concentration 
and spectral characteristics were measured using 
NanoDrop Spectrophotometer ND1000 (PEQLAB, 
Biotechnolo gie GmbH).
Reverse transcription and quantitative PcR 
analysis. QuaniTect Reverse Transcription Kit 
(QIAGEN, Germany) was used for cDNA synthe-
sis according to manufacturer protocol. The ex-
pression levels of MYBL1, TCF3, TCF8, SNAI2, 
MEST, GTF2B and GTF2F2 mRNAs as well as 
acTB mRNA were measured in U87 glioma cells 
and their dnERN1 subline by real-time quantitative 
polymerase chain reaction using Mx 3000P QPCR 
(Stratagene, USA) or “RotorGene RG-3000” qPCR 
(Corbett Research, Germany) and Absolute qPCR 
SYBRGreen Mix (Thermo Fisher Scientific, AB-
gene House, UK). Polymerase chain reaction was 
performed in triplicate using specific primers, which 
were received from Sigma-Aldrich (St. Louis, MO, 
USA). 
For amplification of MyBl1 cDNA we used 
forward (5′–TTGAAGGATGCGAAGAGGT–3′) and 
reverse (5′–CATCGATGCTGGCACTGAAA–3′) 
primers. The nucleotide sequences of these prim-
ers correspond to sequences 401-420 and 637-618 of 
human MyBl1 cDNA (GenBank accession number 
NM_001080416). The size of amplified fragment is 
237 bp. 
The amplification of TcF3 cDNA for real 
time RCR analysis was performed using two 
oligonucleotides primers: forward – 5′–ACAA-
GGAGCTCAGTFACCTC–3′ and reverse – 5′–CT-
GTFCGACTCAGTFAAGTF–3′. The nucleotide se-
quences of these primers correspond to sequences 
107-126 and 326-307 of human TcF3 cDNA (Gen-
Bank accession number NM_003200). The size of 
amplified fragment is 220 bp.
The amplification of TcF8 cDNA for real time 
RCR analysis was performed using two oligonucleo-
tides primers: forward – 5′–CAGGGAGGAGCAGT-
FAAAGA–3′ and reverse – 5′–CTCTTCAGGTFC-
CTCAGGAA–3′. The nucleotide sequences of these 
primers correspond to sequences 209-228 and 438-
419 of human TcF8 cDNA (GenBank accession 
number NM_030751). The size of amplified frag-
ment is 230 bp. 
For amplification of SNaI2 cDNA we used for-
ward (5′–CCTGGTTGCTTCAAGGACAC–3′ and 
reverse (5′–AGCAGCCAGATTCCTCATGT–3′) 
primers. The nucleotide sequences of these pri mers 
correspond to sequences 765-784 and 968-949 of 
human SNaI2 cDNA (GenBank accession number 
NM_003068). The size of amplified fragment is 
204 bp.
For amplification of MeST cDNA we used for-
ward (5′–TTGGCTTCAGTGACAAACCG–3′ and 
reverse (5′–TGACAGCACACCTCCATCTT–3′) 
primers. The nucleotide sequences of these pri mers 
correspond to sequences 576-595 and 859-840 of 
human MEST cDNA (GenBank accession number 
NM_002402). The size of amplified fragment is 
284 bp. 
The amplification of GTF2F2 cDNA was 
performed using two oligonucleotide primers: for-
ward – 5′–GGAGTGTGGCTAGTCAAGGT–3′ and 
reverse – 5′–GCACTGACTGAAGCTGGTTT–3′. 
The nucleotide sequences of these primers cor-
respond to sequences 209-228 and 390-371 of hu-
man GTF2F2 cDNA (GenBank accession number 
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NM_004128).  The size of amplified fragment is 182 
bp. 
For amplification of GTF2B cDNA we used 
forward (5′–TCTGTTGTGTCTTGTTGCGG–3′ and 
reverse (5′–GTTCGCCATTCAGATCCCAC–3′) 
primers. The nucleotide sequences of these prim-
ers correspond to sequences 80-99 and 280-261 of 
human GTF2B cDNA (GenBank accession num-
ber NM_001514). The size of amplified fragment is 
201 bp. 
The amplification of β-actin (ACTB) cDNA 
was performed using forward – 5′–GGACTTCGAG-
CAAGAGATGG–3′ and reverse – 5′–AGCACTGT-
GTTGGCGTACAG–3′ primers. These primer nucle-
otide sequences correspond to 747-766 and 980-961 
of human ACTB cDNA (GenBank accession num-
ber NM_001101). The size of amplified fragment is 
234 bp. The expression of β-actin mRNA was used 
as control of analyzed RNA quantity. 
Quantitative PCR analysis was performed 
using a special computer program “Differential ex-
pression calculator”. The values of MyBl1, TcF3, 
TcF8, SNaI2, MeST, GTF2B, GTF2F2 and acTB 
gene expressions were normalized to the expres-
sion of β-actin mRNA and represented as percent of 
control (100 %). All values are expressed as mean ± 
SEM from triplicate measurements performed in 4 
independent experiments. 
Statistical analysis. The statistical hypothe ses 
were tested using the STATISTICA v.7 for every 
gene: MeST, MyBl1, TcF3, TcF8, GTF2B, SNaI2, 
and GTF2F2. The samples were normally distribu-
ted. It follows from the sampling process and testing 
with Normal-Probability Plot. Effect of hypoxia in 
dnERN1 cells was evaluated with Wald-Wolfowitz 
and Mann-Whitney tests as a nonparametric alterna-
tive to the t-test for independent samples. All three 
tests delivered similar outcomes. 
results and discussion 
We investigated the effect of hypoxic condi-
tions on the expression of a subset of genes enco-
ding proliferation and migration related transcrip-
tion factors as well as a potential tumor suppressor 
MeST in U87 glioma cells in relation to functional 
activity of IRE1 signaling enzyme. We determined, 
that in control U87 glioma cells, transfected with 
an empty pcDNA3.1 vector, hypoxia led to a mode-
rate down-regulation (-32%) of the expression of 
MyBl1 mRNA (Fig. 1). In cells with IRE1/ERN1 
knockdown (dnERN1) we also observed a decreased 
expression of this transcription factor (-23%) under 
hypoxic conditions, in comparison to cells cultivated 
with normal amounts of oxygen. Therefore, inhibi-
tion of IRE1 signaling enzyme in glioma cells did 
not significantly affect the hypoxic regulation of 
MYBL1 expression, though in glioma cells with 
IRE1 knockdown we observed a 6-fold increase in 
MyBl1 mRNA levels in comparison to cells, ex-
pressing native IRE1 (Fig. 1).  
As shown in Fig. 2, hypoxia did not affect the 
expression levels of TcF3 mRNA in control U87 
glioma cells. However, inhibition of IRE1 kinase 
and RNase introduced sensitivity to hypoxia of 
this gene’s expression. Namely, mRNA levels of 
TCF3 transcription factor in dnERN1 glioma cells 
were up-regulated (+32%) under hypoxic conditions 
(Fig. 2). Therefore, in case of TCF3, treatment with 
hypoxia augmented the effect of IRE1 inhibition on 
the expression of this gene. 
Fig. 1. Effect of hypoxia (3% oxygen – 16h) on the ex-
pression level of transcription factor MyBl1 in con-
trol U87 glioma cells (Vector)  and cells with inhi-
bition of IRe1/eRN1 enzymatic activities (dneRN1) 
measured by qPcR. The values of MyBl1 mRNa 
expression were normalized to beta-actin mRNa 
level and presented as percent of control (100%); 
n = 4
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We demonstrate, that hypoxia led to a marked 
(-58%) down-regulation of TCF8 expression in U87 
glioma cells (Fig. 3). In cells, expressing dominant-
negative IRE1/ERN1, we observed decreased ex-
pression of this transcription factor mRNA (-28%) 
under hypoxic conditions in comparison to dnERN1 
cells, which were cultivated with normal amounts of 
oxygen (Fig. 3). Thus, we can conclude, that IRE1 
inhibition in U87 glioma cells decreased the sensi-
tivity of TCF8 expression to hypoxia. 
We observed, that low levels of oxygen led to a 
marked (+74%) up-regulation of SNaI2 mRNA ex-
pression in U87 glioma cells, transfected with empty 
vector (Fig 4). At the same time, in dnERN1 cells 
hypoxic conditions led only to a 16% increase in ex-
pression of this transcription factor mRNA (Fig.4). 
Therefore, as in case of TCF8 inhibition of IRE1 
signaling enzyme in glioma cells led to decreased 
sensitivity of SNAI2 expression to hypoxia. At the 
same time, in glioma cells with IRE1 knockdown 
Fig. 2. Effect of hypoxia (3% oxygen – 16 h) on the 
expression level of transcription factor TcF3 in con-
trol U87 glioma cells (Vector) and cells with inhibi-
tion of IRe1/eRN1 enzymatic activities (dneRN1) 
measured by qPcR. The values of TcF3 mRNa 
expression were normalized to β-actin mRNA level 
and presented as percent of control (100%); n = 4
Fig. 3. Effect of hypoxia (3% oxygen – 16 h) on the 
expression level of transcription factor TcF8 in con-
trol U87 glioma cells (Vector) and cells with inhibi-
tion of IRe1/eRN1 enzymatic activities (dneRN1) 
measured by qPcR. The values of TcF8 mRNa 
expression were normalized to β-actin mRNA level 
and presented as percent of control (100%); n = 4
we observed a prominent up-regulation of SNAI2 
expression in comparison to control cells with na-
tive IRE1 (Fig. 4). Moreover, hypoxic treatment of 
dnERN1 cells augmented the effect of IRE1 inhibi-
tion on the expression of SNAI2. 
In case of potential tumor suppressor MEST, 
its expression was up-regulated almost 2-fold in U87 
glioma cells subjected to hypoxia (Fig. 5). Inhibi-
tion of IRE1 signaling enzyme in glioma cells led to 
more than 8-fold increase in expression of its mRNA 
in comparison to cells with native IRE1 (Fig. 5). Fur-
thermore, hypoxic treatment of dnERN1 cells re-
sulted in 28% increase in MEST expression (Fig. 5). 
Thus, we can conclude, that IRE1 knockdown de-
creased the sensitivity of this gene’s expression to 
hypoxia in U87 glioma cells. 
Hypoxia did not affect significantly the ex-
pression of general transcription factor 2B in U87 
glioma cells with native IRE1 (Fig. 6). Upon inhibi-
tion of IRE1 we observed a 60% decrease in expres-
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Fig. 4. Effect of hypoxia (3% oxygen – 16 h) on the 
expression level of transcription factor SNaI2 in 
control U87 glioma cells (Vector) and cells with inhi-
bition of IRe1/eRN1 enzymatic activities (dneRN1) 
measured by qPcR. The values of SNaI2 mRNa 
expression were normalized to β-actin mRNA level 
and presented as percent of control (100%); n = 4
Fig. 5. Effect of hypoxia (3% oxygen – 16 h) on the 
expression level of gene MeST in control U87 glio-
ma cells (Vector) and cells with inhibition of IRe1/
eRN1 enzymatic activities (dneRN1) measured by 
qPcR. The values of MeST mRNa expression were 
normalized to β-actin mRNA level and presented as 
percent of control (100%); n = 4
sion of this transcription factor, and hypoxia slightly 
increases the expression of GTF2B gene in glioma 
cells with IRE1 knockdown (Fig. 6). In contrast, 
treatment with hypoxia led to a 46% decrease in 
GTF2F2 mRNA expression in glioma cells (Fig. 7). 
Moreover, in dnERN1 glioma cells, subjected to hy-
poxia, the expression of GTF2F2 was further down-
regulated (-64%) in comparison to control dnERN1 
cells, cultivated with normal amounts of oxygen 
(Fig. 6). Thus, the hypoxic regulation of GTF2F2 
expression in glioma cells is IRE1-dependent and 
inhibition of IRE1 increases the effect of hypoxia on 
the expression of this transcription factor.
In this work we studied the expression of a 
number of proliferation-related transcription factor 
genes, as well as of a potential tumor suppressor 
MeST in U87 glioma cells with an unaltered IRE1 
signaling enzyme and in cells with IRE1 knockdown 
upon hypoxic conditions. The aim of the study was 
to evaluate the effect of IRE1 inhibition on the hy-
poxic regulation of the expression of selected genes, 
as both hypoxia and ER stress are key factors, which 
control cellular proliferation and tumor growth in 
gliomas and many other types of cancers [35-39]. 
The growing tumor utilizes the endoplasmic reticu-
lum stress and hypoxia responses to promote the for-
mation of new blood vessels, cellular proliferation, 
as well as to acquire resistance to apoptosis [28, 33, 
35]. Numerous data [35, 36, 38-40] is available that 
cellular response to hypoxia is associated with ma-
lignant progression through the endoplasmic reticu-
lum stress signaling pathway, however, the precise 
mechanism of such interconnection remains largely 
unknown.
In this study we have demonstrated that the 
expression of most studied genes, except TcF3 and 
GTF2B in control glioma cells is affected by hypoxia 
as compared to normoxic condition. For instance, the 
expression levels of MeST and SNaI2 genes were 
increased upon hypoxia in U87 glioma cells with na-
tive IRE1, whereas the relative mRNA levels of tran-
scription factors MyBl1, TcF8 and GTF2F2 were 
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Fig. 6. Effect of hypoxia (3% oxygen – 16 h) on the 
expression levels of transcription factors GTF2B in 
control U87 glioma cells (Vector) and cells with inhi-
bition of IRe1/eRN1 enzymatic activities (dneRN1) 
measured by qPcR. The values of GTF2B mRNa 
expression were normalized to β-actin mRNA level 
and presented as percent of control (100%); n = 4
Fig. 7. Effect of hypoxia (3% oxygen – 16 h) on the 
expression levels of transcription factors GTF2B 
and GTF2F2 in control U87 glioma cells (Vector) 
and cells with inhibition of IRe1/eRN1 enzymatic 
activities (dneRN1) measured by qPcR. The val-
ues of GTF2B and GTF2F2 mRNa expression were 
normalized to β-actin mRNA level and presented as 
percent of control (100%); n = 4
decreased under hypoxic conditions in comparison 
to control. Inhibition of IRE1 signaling enzyme in 
glioma cells did not significantly affect the hypoxic 
regulation of MYBL1 expression. 
In case of TCF3 and GTF2B transcription fac-
tors, inhibition of IRE1 signaling enzyme intro-
duces the hypoxic regulation of the expression of 
these genes. In contrast, IRE1 knockdown in U87 
glioma cells decreased the sensitivity of TcF8, 
SNaI2 and MeST expression to hypoxia. Only in 
case of GTF2F2 transcription factor IRE1 inhibi-
tion resulted in increased sensitivity of this gene’s 
expression to hypoxia in glioma cells. 
It is interesting to note, that in all cases treat-
ment with hypoxia did not abolish the effect of IRE1 
knockdown on the expression of studied genes. 
Moreover, in case of pro-migratory transcription 
factors TCF3 and SNAI2, hypoxic treatment of 
dnERN1 cells augmented the effect of IRE1 inhibi-
tion on the expression of these genes. It is known, 
that suppression of IRE1 enzymatic activities in 
gliomas leads to the inhibition of tumor neovascu-
larization together with the development of a more 
invasive phenotype [33, 34]. It is reasonable to sug-
gest, that combined impact of hypoxia and IRE1 
inhibition on the expression of key pro-migratory 
transcription factors may contribute to the increased 
migration potential of IRE1 knockdown glioma cells. 
The present study demonstrates that hypoxia, 
which is a major factor influencing glioma growth, 
affects almost all studied genes expression and that 
inhibition of IRE1 modifies the hypoxic regulation 
of these gene expressions in gene specific manner. 
However, little is known about the detailed molecu-
lar mechanisms of IRE1-mediated hypoxic regula-
tion of these genes.
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Гіпоксична реГуляція 
експресії Генів MYBL1, MEST, 
TCF3, TCF8, GTF2B, GTF2F2 та SNAI2 
у клітинах Гліоми U87 за умов 
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Досліджено вплив пригнічення IRE1/ERN1 
(inositol requiring enzyme 1/ endoplasmic reticulum 
to nucleus signaling 1) на гіпоксичну регуляцію 
експресії низки генів, причетних до контро-
лю проліферації та міграції, в клітинах гліоми 
лінії U87. Показано, що гіпоксія призводить до 
зростання експресії генів MeST та SNaI2, та 
до зниження експресії генів MyBl1, TcF8 та 
GTF2F2 на рівні мРНК у контрольних клітинах 
гліоми. У той же час, гіпоксія не чинить впливу 
на експресію генів транскрипційних факторів 
TCF3 та GTF2B. У свою чергу, інгібування 
IRE1 модифікує вплив гіпоксії на експресію 
всіх досліджуваних генів, за винятком MyBl1 
та GTF2B. Зокрема, виключення IRE1 знижує 
чутливість експресії генів MeST, TcF8 та SNaI2 
до гіпоксії і, навпаки, підвищує чутливість 
експресії гена GTF2F2 до дії даного чинника. У 
той же час, інгібування IRE1 ініціює гіпоксичну 
регуляцію експресії гена TcF3 в клітинах 
гліоми. Показано, що пригнічення IRE1 у 
клітинах гліоми має різноспрямований вплив на 
гіпоксичну регуляцію експресії досліджуваних 
генів, однак, гіпоксія в жодному з випадків не 
усуває впливу пригнічення  IRE1 на їх експресію. 
Навпаки, у випадку SNaI2, GTF2F2 та MeST 
умови гіпоксії посилюють ефект пригнічення 
IRE1 на їх експресію в клітинах гліоми. 
К л ю ч о в і  с л о в а: експресія мРНК, 
MyBl1, TcF3, TcF8, SNaI2, GTF2B, GTF2F2, 
MeST, пригнічення IRE1, гіпоксія, клітини 
гліоми.
Гипоксическая реГуляция 
экспрессии Генов MYBL1, MEST, 
TCF3, TCF8, GTF2B, GTF2F2 и SNAI2 
в клетках Глиомы U87 при 
инГибировании IRE1
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технологий, Киев, Украина 
Исследовано влияние угнетения IRE1/
ERN1 (inositol requiring enzyme 1/ endoplasmic 
reticulum to nucleus signaling 1) на гипоксическую 
регуляцию экспрессии ряда генов, причастных 
к контролю пролиферации и миграции, в клет-
ках глиомы линии U87. Показано, что гипоксия 
ведет к увеличению уровня экспрессии генов 
MeST и SNaI2, и к снижению уровней экспрес-
сии MyBl1, TcF8 и GTF2F2 на уровне мРНК в 
контрольных клетках глиомы. В то же время, 
гипоксия не влияет на экспрессию транскрипци-
онных факторов TCF3 и GTF2B. В свою очередь, 
ингибирование IRE1 модифицирует влияние ги-
поксии на экспрессию всех исследуемых генов, 
кроме MyBl1 и GTF2B. В частности, выключе-
ние IRE1 снижает чувствительность экспрессии 
генов MeST, TcF8 и SNaI2 к гипоксии и, на-
оборот, повышает чувствительность экспрессии 
гена GTF2F2 к влиянию данного фактора. В то 
же время, ингибирование IRE1 инициирует ги-
поксическую регуляцию экспрессии гена TcF3 
в клетках глиомы. Показано, что угнетение IRE1 
в клетках глиомы имеет разнонаправленное 
влияние на гипоксическую регуляцию экспрес-
сии исследуемых генов, однако, ни в одном из 
случаев гипоксия не нивелирует эффект угнете-
ния IRE1 на их экспрессию. Наоборот, в случае 
SNaI2, GTF2F2 и MeST условия гипоксии усили-
вают эффект угнетения IRE1 на их экспрессию в 
клетках глиомы. 
К л ю ч е в ы е  с л о в а: экспрессия мРНК, 
MyBl1, TcF3, TcF8, SNaI2, GTF2B, GTF2F2, 
MeST, угнетение IRE1, гипоксия, клетки глио-
мы.
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